Terms: = Skin cancer AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras AND Clinical Outcome
4 results:
1. Loss of Tpl2 activates compensatory signaling and resistance to EGFR/MET dual inhibition in v-RAS transduced keratinocytes.
Kelley MB; Geddes TJ; Ochiai M; Lampl NM; Kothmann WW; Fierstein SR; Kent V; DeCicco-Skinner K
PLoS One; 2022; 17(3):e0266017. PubMed ID: 35325006
[TBL] [Abstract] [Full Text] [Related]
2. Targeting X-linked inhibitor of apoptosis protein to increase the efficacy of endoplasmic reticulum stress-induced apoptosis for melanoma therapy.
Hiscutt EL; Hill DS; Martin S; Kerr R; Harbottle A; Birch-Machin M; Redfern CP; Fulda S; Armstrong JL; Lovat PE
J Invest Dermatol; 2010 Sep; 130(9):2250-8. PubMed ID: 20520630
[TBL] [Abstract] [Full Text] [Related]
3. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of k-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
Lurje G; Nagashima F; Zhang W; Yang D; Chang HM; Gordon MA; El-Khoueiry A; Husain H; Wilson PM; Ladner RD; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
Clin Cancer Res; 2008 Dec; 14(23):7884-95. PubMed ID: 19047118
[TBL] [Abstract] [Full Text] [Related]
4. BRAF mutations in metastatic melanoma: a possible association with clinical outcome.
Kumar R; Angelini S; Czene K; Sauroja I; Hahka-Kemppinen M; Pyrhönen S; Hemminki K
Clin Cancer Res; 2003 Aug; 9(9):3362-8. PubMed ID: 12960123
[TBL] [Abstract] [Full Text] [Related]